Does the dosing and infusion of intravenous immunoglobulin (IVIG) need to be adjusted for a patient receiving veno‑venous extracorporeal membrane oxygenation (VV‑ECMO)?

IVIG Dosing and Infusion in VV-ECMO Patients

Standard IVIG dosing and infusion rates do not require adjustment solely based on VV-ECMO support, though heightened monitoring for volume status and infusion-related complications is essential.

Standard Dosing Applies

The available evidence does not support routine dose modification of IVIG for patients on VV-ECMO. Standard dosing protocols should be followed based on the underlying indication:

• Primary immunodeficiency: 300-600 mg/kg every 3-4 weeks 1
• Autoimmune conditions (ITP, myositis, MIS-C): 1-2 g/kg, typically divided over 1-2 consecutive days 2, 3, 4
• Cardiac transplant rejection: 2 g/kg divided over 2 days 5

Infusion Rate Considerations

Standard infusion protocols should be maintained, starting at 0.01 mL/kg/min (0.5 mg/kg/min) and gradually increasing to a maximum of 0.10 mL/kg/min (5 mg/kg/min) if tolerated 1. However, patients on VV-ECMO warrant special attention:

Volume Management is Critical

• Assess cardiac function and fluid status before IVIG administration 4
• Patients with cardiac dysfunction may require divided dosing (1 g/kg daily over 2 days instead of single-day administration) 4
• For doses exceeding 80 g, consider extending administration over 3-5 days at 0.4 g/kg/day 3

Enhanced Monitoring During Infusion

Monitor continuously for:

• Volume overload - ECMO patients may have compromised cardiac function requiring slower infusion or diuretics 4
• Hemodynamic instability - vital signs should be monitored throughout infusion 1
• Thrombotic complications - ECMO circuits increase baseline thrombosis risk, which IVIG can exacerbate 1

Special Safety Considerations in ECMO

Thrombosis Risk

ECMO patients face compounded thrombotic risk from both the extracorporeal circuit and IVIG-induced hyperviscosity 1. Risk factors include:

• Indwelling central vascular catheters (the ECMO cannulas themselves) 1
• Hyperviscosity from hyperproteinemia 1
• Advanced age, immobilization, and underlying critical illness 1

Consider baseline blood viscosity assessment in high-risk patients before IVIG administration 1.

Renal Function Monitoring

While IVIG does not require dose adjustment for ECMO, ensure adequate hydration and monitor renal function closely 1:

• Check BUN and creatinine before infusion and at appropriate intervals 1
• ECMO patients may have pre-existing renal dysfunction or be receiving nephrotoxic medications
• Administer at minimum effective infusion rate in patients with renal risk factors 1

Hemolysis Monitoring

Monitor for hemolysis, particularly after high-dose IVIG (≥2 g/kg), as ECMO circuits themselves can cause hemolysis 1. This is especially important in non-O blood group patients receiving large IVIG doses 1.

Limited ECMO-Specific Evidence

Two studies examined IVIG use in ECMO patients 6, 7:

• A 2020 study found IVIG administration was safe in ECMO patients with suspected toxin-mediated shock, with no dose adjustments reported 6
• A 2018 study of IgM-enriched immunoglobulin in ARDS patients on ECMO showed no safety concerns with standard dosing, though efficacy was not demonstrated 7

Neither study identified ECMO-specific dosing modifications or infusion rate changes.

Practical Algorithm

1. Determine indication-appropriate IVIG dose (do not reduce for ECMO alone)
2. Assess pre-infusion status:
   • Cardiac function via echocardiography
   • Volume status and need for diuretics
   • Renal function (BUN, creatinine)
   • Blood viscosity if high-risk features present
3. Plan infusion strategy:
   • Standard rate progression for stable patients
   • Consider divided dosing (over 2-3 days) if cardiac dysfunction present
   • Ensure separate IV line from ECMO circuit 1
4. Monitor throughout infusion:
   • Vital signs continuously
   • ECMO flow parameters
   • Signs of volume overload
   • Urine output
5. Post-infusion surveillance:
   • Renal function at 24-48 hours
   • Hemolysis markers if high-dose used
   • Thrombotic complications

Common Pitfalls

• Do not empirically reduce IVIG dose based solely on ECMO support - this may compromise therapeutic efficacy for the underlying indication
• Do not infuse IVIG through ECMO circuit - use separate IV access 1
• Do not overlook volume status - cardiac dysfunction is common in ECMO patients and may necessitate slower infusion or divided dosing 4
• Do not forget anticoagulation interactions - while IVIG dosing doesn't change, the prothrombotic effects are amplified in ECMO patients requiring careful monitoring 1